“For every 1,000 patient-years of PEPFAR-supported HIV treatment provided, 228 fewer HIV patients die, 449 fewer children become orphans, 61 fewer sexual HIV transmissions occur and 26 fewer ‘vertical’ transmissions (e.g. mother-to-child) occur,” John Blanford of the CDC told the PEPFAR Scientific Advisory Board in Washington, D.C., on September 14, according to a post in the Center for Global Health Policy’s “Science Speaks” blog. According to the blog, “PEPFAR developed the antiretroviral therapy (ART) cost model to estimate resource requirements for treatment scale up, utilizing data from the multi-country PEPFAR ART Costing Project Study and other PEPFAR-supported studies” (Mazzotta, 10/5).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.